Feasibility of localized immunosuppression

1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation

Peter Buchwald, N. Bocca, S. Marzorati, G. Hochhaus, N. Bodor, C. Stabler, Norma S Kenyon, Luca A Inverardi, Ruth Molano, Camillo Ricordi, Antonello Pileggi

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Emerging biotechnologies, such as the use of biohybrid devices for cellular therapies, are showing increasing therapeutic promise for the treatment of various diseases, including type 1 diabetes mellitus. The functionality of such devices could be greatly enhanced if successful localized immunosuppression regimens could be established, since they would eliminate the many otherwise unavoidable side effects of currently used systemic immunosuppressive therapies. The existence of local immune privilege at some specialized tissues, such as the eye, CNS, or pregnant uterus, supports the feasibility of localized immunomodulation, and such an approach is particularly well-suited for cell transplant therapies where all transplanted tissue is localized within a device. Following the success of syngeneic transplantation in a subcutaneous prevascularized device as a bioartificial pancreas in a rodent model, we now report the first results of exploratory in vivo islet allograft studies in rats using locally delivered glucocorticoids (dexamethasone phosphate and the soft steroid loteprednol etabonate). Following in vitro assessments, in silico drug distribution models were used to establish tentative therapeutic dose ranges. Sustained local delivery was achieved via implantable osmotic mini-pumps through a central sprinkler, as well as with a sustained-delivery formulation for loteprednol etabonate using poly(D,L-lactic) acid (PLA) microspheres. Doses delivered locally were approximately hundred-fold smaller than those typically used in systemic treatments. While several solubility, stability, and implantation problems still remain to be addressed, both compounds showed promise in their ability to prolong graft survival after tapering of systemic immunosuppression, compared to control groups.

Original languageEnglish
Pages (from-to)421-428
Number of pages8
JournalPharmazie
Volume65
Issue number6
DOIs
StatePublished - Jun 1 2010

Fingerprint

Cell Transplantation
Immunosuppression
Glucocorticoids
Equipment and Supplies
dexamethasone 21-phosphate
Therapeutics
Isogeneic Transplantation
Immunomodulation
Graft Survival
Immunosuppressive Agents
Biotechnology
Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Microspheres
Computer Simulation
Solubility
Uterus
Allografts
Pancreas
Rodentia

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Feasibility of localized immunosuppression : 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation. / Buchwald, Peter; Bocca, N.; Marzorati, S.; Hochhaus, G.; Bodor, N.; Stabler, C.; Kenyon, Norma S; Inverardi, Luca A; Molano, Ruth; Ricordi, Camillo; Pileggi, Antonello.

In: Pharmazie, Vol. 65, No. 6, 01.06.2010, p. 421-428.

Research output: Contribution to journalArticle

Buchwald, Peter ; Bocca, N. ; Marzorati, S. ; Hochhaus, G. ; Bodor, N. ; Stabler, C. ; Kenyon, Norma S ; Inverardi, Luca A ; Molano, Ruth ; Ricordi, Camillo ; Pileggi, Antonello. / Feasibility of localized immunosuppression : 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation. In: Pharmazie. 2010 ; Vol. 65, No. 6. pp. 421-428.
@article{d0389407abb6446f9292374f31bc24df,
title = "Feasibility of localized immunosuppression: 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation",
abstract = "Emerging biotechnologies, such as the use of biohybrid devices for cellular therapies, are showing increasing therapeutic promise for the treatment of various diseases, including type 1 diabetes mellitus. The functionality of such devices could be greatly enhanced if successful localized immunosuppression regimens could be established, since they would eliminate the many otherwise unavoidable side effects of currently used systemic immunosuppressive therapies. The existence of local immune privilege at some specialized tissues, such as the eye, CNS, or pregnant uterus, supports the feasibility of localized immunomodulation, and such an approach is particularly well-suited for cell transplant therapies where all transplanted tissue is localized within a device. Following the success of syngeneic transplantation in a subcutaneous prevascularized device as a bioartificial pancreas in a rodent model, we now report the first results of exploratory in vivo islet allograft studies in rats using locally delivered glucocorticoids (dexamethasone phosphate and the soft steroid loteprednol etabonate). Following in vitro assessments, in silico drug distribution models were used to establish tentative therapeutic dose ranges. Sustained local delivery was achieved via implantable osmotic mini-pumps through a central sprinkler, as well as with a sustained-delivery formulation for loteprednol etabonate using poly(D,L-lactic) acid (PLA) microspheres. Doses delivered locally were approximately hundred-fold smaller than those typically used in systemic treatments. While several solubility, stability, and implantation problems still remain to be addressed, both compounds showed promise in their ability to prolong graft survival after tapering of systemic immunosuppression, compared to control groups.",
author = "Peter Buchwald and N. Bocca and S. Marzorati and G. Hochhaus and N. Bodor and C. Stabler and Kenyon, {Norma S} and Inverardi, {Luca A} and Ruth Molano and Camillo Ricordi and Antonello Pileggi",
year = "2010",
month = "6",
day = "1",
doi = "10.1691/ph.2010.0525R",
language = "English",
volume = "65",
pages = "421--428",
journal = "Die Pharmazie",
issn = "0031-7144",
publisher = "Govi-Verlag Pharmazeutischer Verlag GmbH",
number = "6",

}

TY - JOUR

T1 - Feasibility of localized immunosuppression

T2 - 1. Exploratory studies with glucocorticoids in a biohybrid device designed for cell transplantation

AU - Buchwald, Peter

AU - Bocca, N.

AU - Marzorati, S.

AU - Hochhaus, G.

AU - Bodor, N.

AU - Stabler, C.

AU - Kenyon, Norma S

AU - Inverardi, Luca A

AU - Molano, Ruth

AU - Ricordi, Camillo

AU - Pileggi, Antonello

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Emerging biotechnologies, such as the use of biohybrid devices for cellular therapies, are showing increasing therapeutic promise for the treatment of various diseases, including type 1 diabetes mellitus. The functionality of such devices could be greatly enhanced if successful localized immunosuppression regimens could be established, since they would eliminate the many otherwise unavoidable side effects of currently used systemic immunosuppressive therapies. The existence of local immune privilege at some specialized tissues, such as the eye, CNS, or pregnant uterus, supports the feasibility of localized immunomodulation, and such an approach is particularly well-suited for cell transplant therapies where all transplanted tissue is localized within a device. Following the success of syngeneic transplantation in a subcutaneous prevascularized device as a bioartificial pancreas in a rodent model, we now report the first results of exploratory in vivo islet allograft studies in rats using locally delivered glucocorticoids (dexamethasone phosphate and the soft steroid loteprednol etabonate). Following in vitro assessments, in silico drug distribution models were used to establish tentative therapeutic dose ranges. Sustained local delivery was achieved via implantable osmotic mini-pumps through a central sprinkler, as well as with a sustained-delivery formulation for loteprednol etabonate using poly(D,L-lactic) acid (PLA) microspheres. Doses delivered locally were approximately hundred-fold smaller than those typically used in systemic treatments. While several solubility, stability, and implantation problems still remain to be addressed, both compounds showed promise in their ability to prolong graft survival after tapering of systemic immunosuppression, compared to control groups.

AB - Emerging biotechnologies, such as the use of biohybrid devices for cellular therapies, are showing increasing therapeutic promise for the treatment of various diseases, including type 1 diabetes mellitus. The functionality of such devices could be greatly enhanced if successful localized immunosuppression regimens could be established, since they would eliminate the many otherwise unavoidable side effects of currently used systemic immunosuppressive therapies. The existence of local immune privilege at some specialized tissues, such as the eye, CNS, or pregnant uterus, supports the feasibility of localized immunomodulation, and such an approach is particularly well-suited for cell transplant therapies where all transplanted tissue is localized within a device. Following the success of syngeneic transplantation in a subcutaneous prevascularized device as a bioartificial pancreas in a rodent model, we now report the first results of exploratory in vivo islet allograft studies in rats using locally delivered glucocorticoids (dexamethasone phosphate and the soft steroid loteprednol etabonate). Following in vitro assessments, in silico drug distribution models were used to establish tentative therapeutic dose ranges. Sustained local delivery was achieved via implantable osmotic mini-pumps through a central sprinkler, as well as with a sustained-delivery formulation for loteprednol etabonate using poly(D,L-lactic) acid (PLA) microspheres. Doses delivered locally were approximately hundred-fold smaller than those typically used in systemic treatments. While several solubility, stability, and implantation problems still remain to be addressed, both compounds showed promise in their ability to prolong graft survival after tapering of systemic immunosuppression, compared to control groups.

UR - http://www.scopus.com/inward/record.url?scp=77955296944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955296944&partnerID=8YFLogxK

U2 - 10.1691/ph.2010.0525R

DO - 10.1691/ph.2010.0525R

M3 - Article

VL - 65

SP - 421

EP - 428

JO - Die Pharmazie

JF - Die Pharmazie

SN - 0031-7144

IS - 6

ER -